The Fibroblast Growth Factor Receptor-4 Arg388 Allele Is Associated with Higher Grade and Lymphovascular Space Invasion in Endometrioid Type of Endometrial Adenocarcinoma
BA Clarke, MD Ghazarian, S Ezzat, SL Asa. University Health Network, Toronto, ON, Canada
Background: Recent studies have shown that a single nucleotide polymorphism at codon 388 of fibroblast growth factor 4 (FGFR-4) is associated with worse prognosis in patients with breast, colorectal, and prostate cancer and with high grade soft tissue sarcomas.
Design: Tissue samples from 134 patients with endometrial adenocarcinoma were obtained. Genotyping of the FGFR 4 Gly388Arg polymorphism was determined by restriction fragment length polymorphism assay. The genotype was correlated with clinical and pathological markers of disease aggressiveness.
Results: We examined FGFR4 polymorphism status in 134 endometrial cancers of which, 28 were serous, 79 were endometrioid, 6 were clear cell, and 21 were mixed. Results were obtained in 131 cases and overall, 51 (39%) patients were wild type, 71 (54%) were heterozygous and 9 (7%) were homozygous for the polymorphism. When cases with the FGFR4 polymorphism (heterozygous and homozygous) versus wild type was anlaysed in the entire cohort, no association with cell type or outcome was found. Subtype-specific analysis revealed an association with higher grade, presence of lymphovascular space invasion and recurrence in the endometrioid subtype. No such association was seen in other cell types.
Conclusions: Homozygosity and heterozygosity for the fibroblast growth factor receptor-4 Arg388 allele is associated with higher grade and lymphovascular space invasion in endometrioid type of endometrial adenocarcinoma.
Wednesday, March 11, 2009 1:00 PM
Poster Session VI # 146, Wednesday Afternoon